AGP Executive Report

Women’s Health & Trust: A new report traces how the contraceptive pill—once a symbol of liberation—has lost ground in parts of Europe, with France seeing a sharp drop in pill use since 2005 as IUDs rise. Gut Health & Ageing: Researchers report a newly identified decline in nerve-to-muscle signaling with age, offering a fresh angle on why strength drops in older adults. Crohn’s Surge: Coverage highlights rising Crohn’s rates among young people in the US and links the trend to modern lifestyle and childhood exposures, while noting the disease’s long-term cancer risk. Obesity Drug Race: Lilly’s mid-stage obesity combo (EloraTZP) is reported to outperform Zepbound in people with diabetes, adding to the fast-moving GLP-1/dual-agonist competition. Health Financing in Africa: President John Mahama urges “health sovereignty,” arguing healthcare should be treated as an investable growth sector, not just a budget cost. Denmark-linked Pharma: Danish biotech Breye Therapeutics raises €67.5m to advance oral therapies for early retinal diseases. Cancer Treatment Update: Genmab reports durable responses for rinatabart sesutecan in platinum-resistant ovarian cancer.

Cancer Drug Update (Denmark): Genmab reported Part C Phase 1/2 RAINFOL™-01 results for rinatabart sesutecan (Rina-S) in platinum-resistant ovarian cancer, with a confirmed objective response rate of 45.9% and median progression-free survival of 9.5 months, including responses even in low FRα expressers. Metabolic Science (Denmark): University of Copenhagen researchers highlighted SLC25A34 as a “master switch” linking the body clock, cold exposure and diet to brown-fat energy use; a Denmark-led EVITA trial also found 1,000 mg/day vitamin C in people at risk of blood cancer changed inflammatory signals and reduced some complications. Public Health Policy (Africa): President John Dramani Mahama urged African leaders to treat health as an investable economic sector to build “health sovereignty,” arguing health spending boosts jobs, manufacturing and stability. Cardiovascular Risk: A Denmark- and Spain-led study found silent artery plaque in 57.1% of adults without known cardiovascular disease, rising from about 1 in 13 under 30 to nearly all by age 60–70. Care Access & Safety: A doctor-led GLP-1 service in South Africa is expanding virtual access amid regulator crackdowns on illegal compounding.

Health Sovereignty Push: African Union forum keynote speaker President John Dramani Mahama urged leaders to treat healthcare as an investable, high-growth sector to build “health sovereignty” and protect economic growth for 1.4 billion Africans. Cardiovascular Screening Gap: A large international study found silent artery plaque in 1 in 13 adults aged 18–29 and in 57% overall—suggesting heart disease starts far earlier than many realize. Early Detection Tech: Yale researchers report an AI-read ECG that can flag people at risk of amyloid cardiomyopathy, aiming to prompt earlier follow-up before irreversible damage. Breast Cancer Access: Eurostat data show Denmark leads mammography participation (82.1% of women 50–69 screened), while Cyprus has high unit availability but low screening uptake. Denmark-linked Pharma Update: Novo Nordisk said the US FDA extended review of its hemophilia A drug denecimig due to manufacturing remediation, with no new decision date but no change to its 2026 outlook. Obesity Drug Pipeline: Zealand Pharma’s survodutide results and stock concerns continue to ripple, as developers race to differentiate next-gen weight-loss options. Disability & Care Policy Watch (UK): Reports say UK plans could cut disability benefits for under-25s and reshape adult social care funding—an issue with knock-on effects for health services.

Novo Nordisk FDA delay: The US FDA extended its review of Novo’s hemophilia A drug denecimig because remediation is still ongoing at a manufacturing site, with no new decision date yet; Novo says safety/efficacy data aren’t flagged and the delay won’t change its 2026 outlook. Breye Therapeutics funding: Denmark’s Breye Therapeutics raised €67.5m to advance oral therapies for early retinal diseases, with Novo Holdings backing. Vitamin C trial in blood cancer risk: Denmark-and-US EVITA phase 2 results suggest vitamin C didn’t change the main cancer-growth measure, but did shift inflammatory signaling and was linked to fewer anemia, pneumonia, arthritis and internal bleeding cases (with more GI problems). AI ECG for amyloid: A Yale-led JAMA study reports an AI read of routine ECG photos can flag people at risk of amyloid cardiomyopathy earlier, aiming to guide who needs further imaging. Breast screening access: Eurostat data show Denmark leads on mammography participation (82.1%), while Cyprus has high unit availability but low screening uptake. PFAS spotlight: A Croatian report highlights “forever chemicals” concerns, with one participant reporting the highest PFAS levels among tested subjects. Danish ethics: Denmark’s ethics council recommends abolishing anonymous sperm and egg donation. Maternity litigation pressure: A UK-focused piece argues maternity services face an unsustainable litigation problem.

Novo Nordisk & FDA: The US FDA has extended its review of Novo Nordisk’s experimental hemophilia A drug denecimig due to ongoing manufacturing remediation, with no new safety or effectiveness concerns; Novo still targets a US launch in the first half of 2027. Danish biotech funding: Breye Therapeutics raised €67.5m in an oversubscribed Series A to advance danegaptide, an oral treatment for early diabetic retinopathy. Cancer vaccine update (Denmark-based): Evaxion will present new immune data for its personalized cancer vaccine EVX-01 at SITC 2026, including systemic effects when combined with pembrolizumab. Local care workforce: Frederiksberg discussed Filipino recruitment for Denmark’s elder-care sector with the Philippine ambassador, as municipalities face ongoing staffing pressure. Brain-tech research: DTU and partners unveiled a needle-thin microfluidic brain implant (mAxialtrode) designed to record, deliver drugs, and stimulate multiple brain regions with reduced tissue damage. Clinical evidence (cardio): A Scandinavian trial found no benefit of aspirin after treatment of colorectal cancer liver metastases. Public health & policy: Denmark’s ethics council recommends abolishing anonymous sperm and egg donation.

Danish Health Tech Breakthrough: Researchers at DTU and the University of Copenhagen unveiled a needle-thin microfluidic brain implant that can record neural activity, deliver drugs, and stimulate multiple brain regions—aimed at advancing epilepsy research and future therapies. Neuro & Pharma Pipeline: Lundbeck will present new movement-disorders data at MDS 2026, including Phase III results for amlenetug in multiple system atrophy and additional Parkinson’s programme updates. Local Life-Sciences Deal: Samfara completed its acquisition of Chr. Olesen Synthesis near Copenhagen, expanding controlled-substance API manufacturing for medicines including buprenorphine and ADHD treatments. Weight-Loss Drug Science: A Danish study suggests more people with overweight could benefit from GLP-1s for heart protection, while separate research in the US reports a sharp rise in postpartum GLP-1 prescriptions. Public Health & Screening: A Europe-wide project reports that type 1 diabetes screening in children can be implemented across countries, supporting earlier detection strategies. Workplace Wellbeing: ISS and Tryg signed a new integrated facility-services partnership across Scandinavia, starting in 2027. AI & Safety: A study says AI-written text can evade detection tools using a simple method, raising new concerns for content rules.

Weight-loss drug shake-up in Denmark: Zealand Pharma’s survodutide (with Boehringer Ingelheim) again underwhelmed in Phase 3, with results showing up to 13.1% weight loss in one analysis but lower figures in another, and Denmark-listed shares sliding as GI side effects and patient dropouts remain a key concern. Next-gen obesity pipeline: Zealand also highlighted peer-reviewed Phase 3 results for its weekly amylin-based petrelintide, reporting about 8.7–10.7% average weight loss vs 1.7% on placebo, with nausea reported in 20% (vs 6%). Diabetes prevention research: A European consortium presented pilot screening for type 1 diabetes in children across eight countries, arguing population screening could be rolled out with staged testing ages. Cardiovascular prevention insight: A large international study led from Copenhagen found “silent” atherosclerosis in 57.1% of symptom-free adults, published alongside the REACT project. EU digital rules: The EU KIDS Act proposes age limits, safety-by-design and age assurance for minors online, with Denmark already consulting on a minimum age of 15 for some social media. Public health equity in care: A Danish registry study found unemployed or retired people with newly diagnosed type 2 diabetes and cardiovascular disease were less likely to start cardioprotective glucose-lowering drugs.

Cardiovascular Prevention: A Danish-led international study found silent artery plaque in 57.1% of symptom-free adults under 60, published in NEJM—reinforcing that heart disease can start long before people feel unwell. Diabetes Care Equity: In a nationwide Danish cohort of newly diagnosed type 2 diabetes plus cardiovascular disease, unemployed or retired patients were less likely to start guideline-recommended cardioprotective drugs, pointing to socioeconomic gaps in treatment. Obesity Drug Watch (Denmark): Zealand Pharma’s survodutide Phase III readout met key endpoints, but reports of high gastrointestinal dropout rates again rattled investors; separate Zealand data on petrelintide showed about 10% weight loss with nausea in 20%. Next-Gen Weight-Loss Competition: Novo and Eli Lilly are pushing oral obesity options and new combination approaches, while Denmark’s Novo also moves to expand oral GLP-1/GIP rights via a major Hengrui deal. Public Health Policy (Denmark): The Danish Council on Ethics recommends ending anonymous sperm and egg donation, citing donor-conceived people’s right to know genetic origins. Food & Nutrition: Arla plans €63m to expand skyr and cottage cheese capacity as demand for protein-rich foods keeps rising. Research & Tech: Danish researchers unveiled a tiny brain implant for recording, stimulating, and delivering fluids in mice—still far from patients, but promising for future seizure research.

Emergency Care Tech: Apple expanded Emergency SOS via satellite to Norway for iPhone 14–16, helping people call for help even without cellular or Wi‑Fi—an important boost for remote areas. Vaccine Research Integrity: A Danish researcher’s guilty plea over grant fraud is being misused online to claim invalid vaccine science; the journal and other experts say the original MMR safety findings still stand. Cancer Prevention: WHO research estimates infections contribute to about 1 in 8 cancer cases in 2024, underscoring the value of screening and infection control. Women’s Health & Safety: A large Danish study links oral menopausal hormone therapy to higher thrombotic risk, while patches appear not to carry the same increase. Obesity Drug Race: Novo Nordisk and Eli Lilly intensified competition with new oral obesity data and trial results, including real-world findings on switching from injections to oral Wegovy. Diabetes Drug Reassurance: Nordic registry results suggest semaglutide users are no more likely to develop pancreatic cancer than other diabetes drug users, though follow-up was under two years. Mental Health & Environment: A study reports seasonal allergies may correlate with higher suicide risk during high-pollen periods. Healthcare System Updates: New consensus diagnostic criteria for acute severe ulcerative colitis aim to modernize outdated measures and improve emergency care decisions.

Novo Nordisk & Obesity Pills: Real-world OCTANE data show people switching from injectable obesity drugs to Novo’s once-daily oral Wegovy lost an average 4.1% body weight in three months, with clinical obesity dropping from 87.1% to 65.5%, as Novo defends its oral lead in a market dominated by GLP-1 competition. Genomics Collaboration: The Novo Nordisk Foundation renews and expands its Broad Institute Center for Genomic Mechanisms of Disease with $53m, pairing U.S. and Denmark teams to decode drivers of type 2 diabetes and obesity. Gut Health Innovation: Danish biotech Bactolife enters the U.S. via Healthgevity, launching Gutgevity using Helm binding proteins designed to bind and neutralise gut compounds. New Colitis Criteria: Updated consensus diagnostic criteria for acute severe ulcerative colitis aim to modernise older rules, including how corticosteroids can affect clinical and lab thresholds. AI Shift in Medicine: A report says AI is moving healthcare from detecting disease to predicting where health is heading, using blood proteins and ageing signals. Denmark Economy: Statistics Denmark reports GDP up 0.9% in Q2, with analysts pointing to stronger production at Danish firms abroad, including Novo. Pet Anxiety Awareness (Denmark included): Pet Anxiety Awareness Day launches in Europe Oct 12 with clinic-based education, rolling out across Sweden, Norway, Denmark and more.

Obesity & diabetes drug news: Zealand Pharma says its Phase 2 ZUPREME-1 results for petrelintide are now published in The Lancet Diabetes & Endocrinology, with EASD 2026 presentations highlighting double-digit weight loss and cardiometabolic improvements, plus fewer GI side effects than typical incretin options. Metabolic health & cancer risk: A new study presented at EASD links type 2 diabetes with higher cancer rates, especially obesity-related cancers, with the gap widening over decades. Diabetes trends in youth: Separate EASD data point to rising type 1 and type 2 diabetes among young people in the US, underscoring the case for earlier metabolic screening. Muscle aging research: Scientists report a molecular driver of age-related muscle decline and suggest targeting a nuclear receptor (ERRγ) could help preserve muscle function. Pharma deal watch (Denmark): Reuters reports Lundbeck is exploring a potential takeover of Xeris, while Novo Nordisk’s oral obesity pipeline deal with Hengrui (HRS-1596) moves forward with exclusive rights outside mainland China. Policy & access: Denmark and other European countries back International Safe Abortion Day with a call for safe, timely, affordable abortion care and decriminalisation.

Novo Nordisk Dealmaking: Novo Nordisk has licensed Hengrui Pharma’s Phase 1-ready once-weekly oral GLP-1/GIP dual agonist HRS-1596 for obesity and type 2 diabetes in a deal worth up to $2.6B (with $300M upfront), underscoring Novo’s push into oral peptides. Diabetes Cardiovascular Claims: Novo says a real-world study found patients escalating Ozempic to 2mg had a 6% lower risk of major cardiovascular events than those switching to Eli Lilly’s Mounjaro (presented at EASD). Diabetic Eye Research Funding: Breye Therapeutics raised €67.5M for danegaptide, an oral candidate for non-proliferative diabetic retinopathy, to move into a randomized Phase 2 trial starting in 2027. Cancer Screening Reassurance: New reanalysis of major mammography trials suggests overdiagnosis risk may be under 5%—lower than older estimates—without changing screening guidelines. Clinical Care Communication: A JAMA piece highlights how physicians’ exercise conversations can make physical activity stick for people with chronic conditions. Nordic Stroke Tech Partnership: Upfront Diagnostics and Vingmed Group will expand rapid stroke diagnostic blood testing across the Nordic region. Brain-Tech Research: Danish and UK teams report a pencil-thin implant that can record, stimulate, and deliver drugs in lab models, not yet for human use. Public Health Caution on Vaping: A systematic review links youth vaping to nicotine dependence, respiratory/oral problems, mental health issues, and later smoking.

Cancer Care Accountability: UK cancer specialists warn an “irreversible cancer epidemic” could follow if government treatment promises aren’t made legally binding, after missed NHS targets and long waits. Denmark–Greenland Security: At the UN, Denmark says a new US-Denmark-Greenland security pact strengthens NATO and Arctic defense while easing tensions over Greenland’s future. Diabetes Risk (Denmark): Danish research links gestational diabetes to developing type 2 diabetes about 13 years earlier, suggesting earlier and potentially more severe disease. Flu Vaccine (Denmark): A pooled analysis presented in Europe finds high-dose flu vaccination cuts flu- and pneumonia-related hospitalizations by 8.8% in older adults with chronic lung disease. Menopause Hormone Safety (BMJ): Danish data show oral menopausal hormone therapy raises venous clot risk, with stroke/heart attack risks varying by dose and duration; transdermal appears safer for clots. Bavarian Nordic Leadership: Copenhagen-based Bavarian Nordic names Big Pharma veteran Tarja Stenvall as next CEO as it pushes global vaccine rollout. HRT Clot Risk (Denmark): Another report highlights oral HRT’s higher clot risk, while patches show a different safety profile. Job-Seeking Residence (Denmark): Denmark lists five qualifying degree levels for foreign graduates to apply for a job-seeking residence permit.

GLP-1 Heart Benefits (Denmark): New EASD research from Copenhagen University Hospital, Herlev suggests extending GLP-1 receptor agonists (like semaglutide and tirzepatide) to more people with BMI 25–26.9 could cut coronary heart disease risk, using Danish/UK data tied to remnant cholesterol and low-grade inflammation. Diabetes Tech in Denmark: Tandem Diabetes Care says its Tandem Mobi automated insulin delivery system is now available in Denmark (and 11 other countries), using Control-IQ+ with Dexcom G7 to adjust insulin every five minutes. Mental Health & Safety (Copenhagen): A man was hospitalized after setting himself on fire at Denmark’s migration and integration agency SIRI in Valby; police say no crime is indicated and witnesses will get crisis support. Cancer Research Capacity (Global, Denmark-linked): Allarity Therapeutics expanded its lab with proteomics and cell line research to deepen mechanism-of-action studies for its oncology pipeline. Public Health Myth-busting: A cardiology expert warns against viral claims that vitamin D plus K2 can “clean” arteries of calcium buildup. Workforce & Care Access (Denmark context): A Danish study also points to more people with overweight potentially benefiting from GLP-1s for heart protection.

Cancer Care in Focus: Denmark’s LAVA-CRLM trial at Rigshospitalet and Herlev Hospital directly compared microwave ablation vs stereotactic radiotherapy for colorectal liver metastases, finding similar tumour control but fewer severe side effects with radiotherapy. Cardiovascular Prevention: A large international scan study found “silent” atherosclerosis in about 57% of adults, including 1 in 13 under age 30, suggesting imaging could catch disease earlier than risk scores alone. Diabetes Treatment Update: The FDA approved Eli Lilly’s once-weekly insulin for type 2 diabetes, joining Novo Nordisk’s weekly option already approved in the EU. AI in Pharma: Novo Nordisk is partnering with Anthropic to speed up drug discovery using AI. Public Health & Environment: SINTEF researchers are developing optical sensors to detect multiple pesticides in water in real time, with help from citizens in Denmark and Ireland. Local Health Tech: A Danish-led quantum study reports room-temperature qubit stability for seconds, potentially easing the need for extreme cooling.

Whole grains for heart health: A new European Heart Journal meta-analysis links 4–6 daily servings of whole grains (about 60–100g) with better weight, cholesterol, blood sugar and blood pressure. GLP-1s under scrutiny: Athletes are increasingly using GLP-1s, and anti-doping regulators are watching closely as performance-enhancing claims and rules collide. Diabetes and cancer risk (Denmark data): A large Danish study reports cancer incidence is higher in people with type 2 diabetes, with the gap widening over 25 years—especially for obesity-related cancers. Breast screening debate (Denmark): A Danish-led reanalysis suggests breast cancer overdiagnosis from mammography screening is lower than often assumed, with estimates under 5% in Denmark. Weekly insulin breakthrough: The FDA approved Eli Lilly’s once-weekly insulin for type 2 diabetes, joining Novo Nordisk’s earlier weekly option—aimed at reducing daily injection burden. Tattoo safety: A Denmark clinic study cited in coverage finds complications are not rare, with allergic reactions and bacterial infections among the main issues. Water safety reminder: Guidance highlights the importance of testing private wells and monitoring contaminants in public systems.